Scarica l'app Stockscreener
14.56
2.45%
-0.35
Precedente Chiudi:
$14.91
Aprire:
$15.15
Volume 24 ore:
364.39K
Relative Volume:
0.33
Capitalizzazione di mercato:
$489.13M
Reddito:
-
Utile/perdita netta:
$-47.20M
Rapporto P/E:
-9.3017
EPS:
-1.5653
Flusso di cassa netto:
$-43.65M
1 W Prestazione:
-10.55%
1M Prestazione:
+34.30%
6M Prestazione:
+96.29%
1 anno Prestazione:
-39.24%
Intervallo 1D:
$14.48
$15.32
Intervallo di 1 settimana:
$14.48
$16.74
Portata 52W:
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Nome
Mbx Biosciences Inc
Settore
Industria
Telefono
(317) 989-3100
Indirizzo
11711 N. MERIDIAN STREET, CARMEL
Confronta MBX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
14.56 | 666.71M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.45 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.07 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-15 | Ripresa | Jefferies | Buy |
| 2025-08-05 | Iniziato | Mizuho | Outperform |
| 2025-07-16 | Iniziato | Oppenheimer | Outperform |
| 2025-04-10 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | JP Morgan | Overweight |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Stifel | Buy |
Mostra tutto
Mbx Biosciences Inc Borsa (MBX) Ultime notizie
Can MBX Biosciences Inc. hit a new high this monthEarnings Trend Report & Trade Opportunity Analysis Reports - newser.com
Predicting MBX Biosciences Inc. trend using moving averages2025 Major Catalysts & Fast Gain Stock Tips - newser.com
What sentiment indicators say about MBX Biosciences Inc. stockJuly 2025 Macro Moves & Free Daily Entry Point Trade Alerts - newser.com
Detecting price anomalies in MBX Biosciences Inc. with AIMarket Performance Report & Reliable Entry Point Alerts - newser.com
What to expect from MBX Biosciences Inc. in the next 30 days2025 Growth vs Value & AI Powered Market Entry Strategies - newser.com
Trend analysis for MBX Biosciences Inc. this weekJuly 2025 Macro Moves & Weekly Consistent Profit Watchlists - newser.com
MBX Biosciences (NASDAQ:MBX) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Is MBX Biosciences Inc. forming a bottoming baseWeekly Risk Report & Entry Point Confirmation Signals - newser.com
Is MBX Biosciences Inc. stock a defensive play in 20252025 Volume Leaders & Daily Price Action Insights - newser.com
How MBX Biosciences Inc. stock compares to market leaders2025 Trading Recap & Low Risk High Reward Ideas - newser.com
Wellington Management Group LLP Increases Stake in MBX Biosciences Inc - GuruFocus
Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - sharewise.com
Advanced analytics toolkit walkthrough for MBX Biosciences Inc.Bull Run & Weekly High Potential Stock Alerts - newser.com
Combining price and volume data for MBX Biosciences Inc.2025 Key Lessons & Consistent Growth Equity Picks - newser.com
Applying Elliott Wave Theory to MBX Biosciences Inc.Portfolio Performance Report & Entry Point Confirmation Signals - newser.com
MBX Biosciences stock down on pricing upsized public offering at $18.00 per share - MSN
MBX Biosciences stock rating reiterated at Market Outperform by Citizens - Investing.com
Insiders Snap Up $54M in Biotech and Offshore Driller Stocks - 24/7 Wall St.
Guggenheim Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $84 - 富途牛牛
Using AI based signals to follow MBX Biosciences Inc.Trade Entry Report & Weekly Chart Analysis and Guides - newser.com
Developing predictive dashboards with MBX Biosciences Inc. dataWeekly Stock Analysis & Low Risk Growth Stock Ideas - newser.com
MBX Biosciences Inc. stock momentum explainedPortfolio Gains Summary & Growth Focused Entry Point Reports - newser.com
Is it too late to sell MBX Biosciences Inc.Bear Alert & AI Powered Buy and Sell Recommendations - newser.com
How MBX Biosciences Inc. stock reacts to bond yieldsM&A Rumor & Short-Term High Return Strategies - newser.com
Will MBX Biosciences Inc. bounce back from current support2025 Key Highlights & Capital Protection Trading Alerts - newser.com
MBX Biosciences Inc Stock Analysis and ForecastEconomic Impact on Stocks & Learn to Think Like a Long-Term Investor - earlytimes.in
Using Bollinger Bands to evaluate MBX Biosciences Inc.Gold Moves & AI Enhanced Trading Signals - newser.com
Analyzing MBX Biosciences Inc. with multi timeframe chartsDividend Hike & Weekly Momentum Picks - newser.com
Platinum Investment Management Ltd. Lowers Stock Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
Hedge Fund and Insider Trading News: George Soros, David Tepper, Warren Buffett, Davidson Kempner, Bridgewater Associates, Jain Global, MBX Biosciences Inc (MBX), United Therapeutics Corp (UTHR), and More - Insider Monkey
Goldman Sachs Group Inc. Has $112,000 Stock Holdings in MBX Biosciences, Inc. $MBX - Defense World
Massive Stock Purchase by MBX Biosciences Director! - TipRanks
Mbx Biosciences Inc Azioni (MBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mbx Biosciences Inc Azioni (MBX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pescovitz Ora H. | Director |
Apr 08 '25 |
Buy |
5.89 |
7,693 |
45,312 |
24,329 |
| GORDON CARL L | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| GORDON CARL L | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| ORBIMED ADVISORS LLC | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| ORBIMED ADVISORS LLC | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| Hawryluk P. Kent | President & CEO |
Feb 04 '25 |
Buy |
10.69 |
50,000 |
534,500 |
448,277 |
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):